Phio Pharmaceuticals Corp (PHIO) Stock Price, Quote & News

Company Profile

Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma a...

Industry: Biotechnology

Sector: Healthcare

Phone: 508 767 3861

Website: phiopharma.com

Address:

11 Apex Drive, Suite 300A PMB 2006, Marlborough, United States

ckruel Nov. 28 at 7:10 PM

$PHIO looking at the monthly chart Phio with news could get a whopper of a short squeeze, jmo

0 · Reply

WildernessRefuge Nov. 28 at 3:33 PM

$PHIO There is a lot of room under that $2.05 warrant ceiling. Good. But, there is a 6 to maybe 10 week wait for the final subject group in cohort 5. So, let's see where the current strength takes the stock price. Good and Bad. ORCA will basically exert control over the stock price near term. Likely Bad. Be a renter, not an owner near term.

0 · Reply

Treechain Nov. 26 at 4:19 PM

$PHIO 24 hour Macd has crossed over turning north low volume climb

0 · Reply

Treechain Nov. 26 at 4:13 PM

$PHIO Phio pharmaceuticals Will be presenting at the deal flow discovery conference in Atlantic City January 28 and 29th 2026. There will be 150 growth stage companies represented there by then they’re very well could be data released from this latest five week trial that has just started.

0 · Reply

transition_state Nov. 26 at 2:58 PM

$PHIO

0 · Reply

Treechain Nov. 26 at 2:50 PM

$PHIO charts are starting to show buy

0 · Reply

Treechain Nov. 26 at 2:28 PM

$PHIO phase 1b enrollment

0 · Reply

Erhnadgzl Nov. 26 at 8:32 AM

$PHIO Preparations have begun for a very big deal that will happen soon.

0 · Reply

Erhnadgzl Nov. 26 at 8:30 AM

$PHIO lets gooo 4 dolar guys

0 · Reply

ckruel Nov. 25 at 9:33 PM

$PHIO On November 25, 2025, Phio Pharmaceuticals announced the completion of patient enrollment in its Phase 1b clinical trial for PH-762, a siRNA compound targeting skin cancer. The trial, which evaluates safety and tolerability, showed promising results with several patients achieving complete or partial responses, and no dose-limiting toxicities observed. This milestone advances PH-762 as a potential treatment for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, with pathology results expected in Q1 2026. Recent price target $14 usd

0 · Reply

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

Nov 17, 2025, 8:45 AM EST - 12 days ago

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Nov 13, 2025, 4:15 PM EST - 15 days ago

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 7, 2025, 10:30 AM EST - 22 days ago

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Nov 7, 2025, 7:45 AM EST - 22 days ago

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Nov 3, 2025, 1:40 PM EST - 25 days ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

Nov 3, 2025, 7:45 AM EST - 26 days ago

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Oct 31, 2025, 10:15 AM EDT - 4 weeks ago

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Oct 21, 2025, 7:45 AM EDT - 5 weeks ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Sep 18, 2025, 7:45 AM EDT - 2 months ago

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Sep 3, 2025, 7:45 AM EDT - 3 months ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 4:15 PM EDT - 3 months ago

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 25, 2025, 3:04 PM EDT - 4 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Jul 25, 2025, 12:36 PM EDT - 4 months ago

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Jul 25, 2025, 7:45 AM EDT - 4 months ago

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Jun 25, 2025, 7:45 AM EDT - 5 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Jun 24, 2025, 7:45 AM EDT - 5 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jun 6, 2025, 7:45 AM EDT - 6 months ago

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

May 19, 2025, 7:45 AM EDT - 6 months ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

May 15, 2025, 4:15 PM EDT - 7 months ago

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 7:45 AM EDT - 7 months ago

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Apr 9, 2025, 7:45 AM EDT - 8 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Apr 3, 2025, 7:45 AM EDT - 8 months ago

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Mar 31, 2025, 4:00 PM EDT - 8 months ago

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Mar 10, 2025, 7:45 AM EDT - 9 months ago

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Mar 5, 2025, 7:45 AM EST - 9 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Feb 20, 2025, 7:45 AM EST - 10 months ago

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Jan 22, 2025, 7:00 AM EST - 11 months ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jan 21, 2025, 4:15 PM EST - 11 months ago

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 16, 2025, 1:00 PM EST - 11 months ago

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 15, 2025, 7:00 AM EST - 11 months ago

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 14, 2025, 7:00 AM EST - 11 months ago

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 13, 2025, 12:45 PM EST - 11 months ago

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Jan 13, 2025, 7:45 AM EST - 11 months ago

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Jan 2, 2025, 7:45 AM EST - 11 months ago

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Dec 23, 2024, 1:15 PM EST - 1 year ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 2:28 PM EST - 1 year ago

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Dec 12, 2024, 9:21 AM EST - 1 year ago

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Dec 10, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Nov 19, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Nov 14, 2024, 5:47 PM EST - 1 year ago

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 10:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 18, 2024, 1:30 PM EDT - 1 year ago

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

Sep 25, 2024, 8:00 AM EDT - 1 year ago

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

ckruel Nov. 28 at 7:10 PM

$PHIO looking at the monthly chart Phio with news could get a whopper of a short squeeze, jmo

0 · Reply

WildernessRefuge Nov. 28 at 3:33 PM

0 · Reply

Treechain Nov. 26 at 4:19 PM

$PHIO 24 hour Macd has crossed over turning north low volume climb

0 · Reply

Treechain Nov. 26 at 4:13 PM

0 · Reply

transition_state Nov. 26 at 2:58 PM

$PHIO

0 · Reply

Treechain Nov. 26 at 2:50 PM

$PHIO charts are starting to show buy

0 · Reply

Treechain Nov. 26 at 2:28 PM

$PHIO phase 1b enrollment

0 · Reply

Erhnadgzl Nov. 26 at 8:32 AM

$PHIO Preparations have begun for a very big deal that will happen soon.

0 · Reply

Erhnadgzl Nov. 26 at 8:30 AM

$PHIO lets gooo 4 dolar guys

0 · Reply

ckruel Nov. 25 at 9:33 PM

0 · Reply

KuruHabesha Nov. 25 at 6:03 PM

$PHIO Starter!

0 · Reply

RetiredOldGeezer Nov. 25 at 5:04 PM

$PHIO Seems weird to me - Old Bob buys stock and then makes announcement - wonder if his dream team did also or just friends and family - but even the pump was ineffective

0 · Reply

JimCramerisadoofus Nov. 25 at 4:40 PM

$PHIO Phio Pharmaceuticals Corp. announced today the completion of enrollment in its ongoing Phase 1b clinical trial of INTASYL siRNA PH-762. In connection with completing enrollment, Phio continues to treat additional patients in the fifth cohort at the highest dose concentration of PH-762. Pathology results for these patients are expected in Q1 2026. PH-762 is a potent silencer of the PD-1 gene implicated in various forms of skin cancer. Thus far, a total of 18 patients with cutaneous carcinomas have completed treatment across five dose escalating cohorts in the Phase 1b trial. The cumulative pathologic response in 16 patients with cSCC include six with a complete response (100% clearance), two with a near complete response (> 90% clearance) and two with a partial response (> 50% clearance). No patients in the study have exhibited clinical progression of disease. To date, there were no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects in the patients.

0 · Reply

newsfile_corp Nov. 25 at 4:30 PM

https://nfne.ws/275716 $PHIO @PhioPharma11803 #immunooncology #INTASYL #PH762 #PHIO #siRNA #Chemicals #Pharmaceutical #Biotechnology #Healt

0 · Reply

RetiredOldGeezer Nov. 25 at 3:26 AM

$PHIO If CEO buys does that mean there is no major announcements coming? Is a CEO have to follow black out rules when doing random transactions?

0 · Reply

LongAllDay Nov. 24 at 9:34 PM

$PHIO CEO bought a used Hyundai worth of shares we are so blessed

0 · Reply

CEOBuysDisclosures Nov. 24 at 8:00 PM

$PHIO CEO purchased 5,000 shares at $1.14 for a total of $5,700. Bitterman Robert J now owns 281,421 shares. https://ceo-buys.com

0 · Reply

PitaPierogi Nov. 24 at 1:45 PM

$PHIO STRONG BUY. 14. LETS GOOOO $SPY $QQQ $SMCI $NVDA

0 · Reply

trader_23 Nov. 24 at 12:07 AM

$PHIO

0 · Reply

PitaPierogi Nov. 22 at 12:02 AM

$PHIO

0 · Reply

DosGatos Nov. 21 at 8:51 PM

$PHIO Santa Geeeeeert is coming he has a bunch of new shares and a reverse split for all the good shareholders!!

1 · Reply

JimCramerisadoofus Nov. 21 at 4:51 PM

$PHIO

0 · Reply

Market Cap	13.24M
Revenue (ttm)	0.00
Net Income (ttm)	-7.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	92,000
Avg Vol	3,586,980
Day's Range	N/A - N/A
Shares Out	10.76M
Stochastic %K	72%
Beta	0.96
Analysts	Sell
Price Target	$14.00